Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICH Suggests Antihypertensive Drug Trials Add Focus On Systolic Measures

Executive Summary

Clinical trials for new antihypertensive drugs need an increased focus on systolic blood pressure reduction, an International Conference on Harmonization draft guidance on antihypertensive drug development states.

You may also be interested in...

ICH Control Group Guidance Fails To Harmonize Requirements - AstraZeneca

The International Conference on Harmonization's clinical trial control groups guidance should offer more specific advice on how to select a control group acceptable to all ICH regulators, AstraZeneca said in recent comments to FDA.

Merck Sees Hyzaar As Counter To Bristol Antihypertensive Vanlev

Merck's defense of its antihypertensive franchise following the launch of Bristol-Myers Squibb's Vanlev will include an emphasis on the efficacy of its angiotensin II/diuretic combination product Hyzaar.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts